what's going on with tirzepatide A Major GLP-1 Drug Shortage Is Over. Some Patients Aren't Celebrating Tirzepatide Mechanism of Weight Loss

Lower fasting insulin and C-peptide Reduced HOMA2-IR (insulin resistance) Improved lipid profile (triglycerides) Raised adiponectin, lowered leptin Better glucose control Liver Fat Retatrutide reduced liver fat content by as much as 76% for MASLD patients, with the majority of the change occurring during the first 24 weeks

Genetic Predispositions in GLP-1 and GIP Signaling Pathways PlexusDx's Precision Peptide Genetic Test examines key variants in GLP1R (rs6923761), GIPR (rs1800437), FTO (rs9939609), and MC4R (rs17782313) that relate to appetite regulation and metabolic response pathways

Furthermore, Nrf2/HO-1 interacts with the NF-KB and JAK-STAT pathways in various contexts: Nrf2/HO-1 can reduce NF-KB phosphorylation and thereby dampen inflammation, whereas proinflammatory cytokines such as TNF- and IL-6, released following NF-KB activation, upregulate HO-1 in a feedback loop (125, 129)

Further, T2DM remains one of the most significant risk factors not only for the development of MASLD but also for the progression of liver fibrosis and the occurrence of liverrelated complications, including HCC (Hosseinkhan et al., 2025

Proprietary blend

The Precision Peptide Genetic Test looks at peptide pathways and does not predict medication response